Sperm Epigenome in Hodgkin Lymphoma

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18-45
SponsorRennes University Hospital

About this trial

Cancer treatments can have long-term effects on fertility. In men, scientific studies suggest that the process of sperm formation (spermatogenesis) may be disrupted even years after recovery, with potential consequences not only for fertility but also for the health of offspring. The effects of chemotherapy on sperm quality, particularly on DNA packaging (chromatin) and the epigenome, remain poorly understood. Therefore, further in-depth studies are needed to determine whether a history of cancer and chemotherapy treatment may impact the health of children fathered by young male survivors.

We therefore propose to conduct a clinical study aimed at better understanding the mechanisms by which chemotherapies affect spermatogenesis. The results could provide answers by identifying the effects of these drugs on the fertility of young male cancer patients in the long term and the sperm epigenome indicative of the health of the progeny.

Eligibility criteria

Qualifiers

Men aged 18 to 45 years

Diagnosed with Hodgkin lymphoma

Treatment-naïve to any cytotoxic therapy

Whose treatment regimen consists of 4 to 6 cycles of ABVD or BrECADD

Disqualifiers

Patient receiving abdominal radiotherapy

Trial design

Treatments tested in this trial

  • Additional semen samples

Treatment groups

50 Participants
are divided into 1 treatment group

Sponsors and collaborators

Rennes University Hospital

Lead sponsor

Institut National de la Recherche Scientifique - Centre Armand Frappier Santé Biotechnologie

Collaborator